An Elsevier journal has corrected a retraction notice after we asked questions about what exactly it was saying — but not before the journal’s editor tried to defend what turned out to be a mistaken passage.
Scientific Reports is taking heat on social media and from data sleuths for publishing a paper implying that the Biblical story of the destruction of Sodom and Gomorrah might have been the retelling of the devastation wrought by an exploding asteroid in or around the year 1,650 BCE.
Kyoto University has fired a researcher after determining that he committed fraud in at least five papers about the deadly Kumamoto earthquake of 2006.
The authors of a 2021 article on “cognitive radio” have lost the paper after the journal learned that they’d pilfered the work from a doctoral dissertation.
“A Cluster-Based Distributed Cooperative Spectrum Sensing Techniques in Cognitive Radio” was published in the proceedings of the 2020 International Conference on Innovative Data Communication Technologies and Application, which was held in Coimbatore, India. The proceedings was a supplement to Innovative Data Communication Technologies and Application, a Springer Nature title.
Cognitive radio, according to Wikipedia, “can intelligently detect whether any portion of the spectrum is in use, and can temporarily use it without interfering with the transmissions of other users.”
A total of 436 papers in two Springer Nature journals are being subjected to expressions of concern, in the latest case of special issues — in this case, “topical collections” — likely being exploited by rogue editors or impersonators.
The move follows the discovery, as we reported in August, of more than 70 papers in a collection in one of the journals, the Arabian Journal of Geosciences, that referred to subjects — aerobics and running wear, for example — seemingly unrelated to geology. That sleuthing began on PubPeer and was broadened by Alexander Magazinov and Guillaume Cabanac. We have now learned that Springer Nature had already been looking into the issues.
Here’s the notice that appears with a list of more than 400 articles from three differenttopicalcollections for the Arabian Journal of Geosciences:
As long-time readers of this blog know, we’ve spilled more than a few pixels on the work of Donald Morisky. His Morisky Medication Adherence Scale (MMAS) has been a financial boon to himself — and the bane of many researchers who have been forced to either retract papers or pay Morisky what they consider to be exorbitant fees to retroactively license the instrument.
But lately things have been a bit rocky for Morisky. Last year, he and his former business associate (read, legal enforcer) found themselves embroiled in a lawsuit which claims, as we reported, that Morisky used:
their company as a personal piggy bank and taking steps to starve the business of clients and funnel money to his family.
And now, a researcher has questioned the validity of the MMAS, arguing that his review of a foundational paper underpinning the instrument shows serious flaws.
A group of researchers at the Wistar Institute in Philadelphia have retracted a paper in Nature for data discrepancies and inconsistencies — as well as missing data. And one of the corresponding authors has left the institution, Retraction Watch has learned.
Leen Kawas, President and CEO of Athira Pharma. (PRNewsfoto/Athira Pharma, Inc.)
A group of researchers at Washington State University has received four expressions of concern for papers whose findings underpin a publicly traded company founded by two of the most senior authors on the articles.
The studies, all of which appeared in the Journal of Pharmacology and Experimental Therapeutics, came from the labs of Joseph Harding, a medical chemist at Washington State, and his colleague Jay Wright. Published between 2011 and 2014, the four articles report on a molecule called angiotensin IV, work which Harding and Wright leveraged to spin-off Athira, a Seattle-based biotech firm developing treatments for conditions including Alzheimer’s and Parkinson’s disease.
The CEO of Athira, formerly known as M3 Biotechnology, is Leen Kawas, once a PhD student at Washington State whose 2011 doctoral dissertation provided figures for this fraught 2011 article in JPET, which earned a correction in 2014. Earlier this year, as STAT reported, Kawas was forced to take a leave of absence from the company over concerns that she altered images in several papers. And there has been other scrutiny of the company.
